Developer docs
API playgroundTry for free, no card

Search company profiles

Sojournix

Full company profile

uuid0003fnr

Namestring
Sojournix
Legal namestring
PEDANGWIN
Company typeenum
Private
Founded yearint
2016
Descriptiontext

Sojournix is a private, clinical-stage biotechnology company founded in 2016 and headquartered in Arlington, Massachusetts, focused on developing innovative therapeutics for women's health and endocrine disorders. The company operates with a small, specialized team of 11-50 employees, consistent with an R&D-driven organization at the preclinical-to-early-clinical stage.

Sojournix has financed its operations primarily through equity capital, completing three disclosed funding rounds that together total approximately $70 million. The most significant was a $44.0 million Series 3 closed in January 2019 and led by RA Capital Management, with participation from Boxer Capital, Frazier Healthcare Partners, Janus Henderson Investors, and Venrock Healthcare Capital Partners. Earlier rounds of $7.0 million (May 2017) and $19.0 million (December 2017) supported the company's earlier development work. The investor base is composed of dedicated healthcare-focused funds, which is consistent with a clinical pipeline rather than a commercial-stage operation.

The company is led by Daniel Grau as President, Chief Executive Officer, and Director, with Peter Lanciano serving as Chairman of the Board and Chairman of the Audit Committee. No commercial products, partnerships, licensing agreements, or revenue-generating activities were disclosed in the source material, and the company's therapeutic pipeline and specific drug candidates were not detailed. Note: scraped content from the sojournixpharma.com domain references unrelated third-party entities (a gambling platform and a footwear brand) and is not consistent with Sojournix's stated biotech focus, suggesting domain repurposing rather than first-party Sojournix content.

Short descriptiontext

Sojournix is a private, clinical-stage biotechnology company founded in 2016 and headquartered in Arlington, Massachusetts, developing therapeutics for women's health and endocrine disorders, backed by approximately $70 million in venture funding from healthcare-focused investors.

Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersWaltham, United States
HQ citystring
Waltham
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
women's health therapeutics, endocrine disorder treatments, clinical-stage biopharmaceuticals, women's health drug development, endocrine medicine pipeline
Industry2 codes
PRIMARYHLAIAAAJ
Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAD
Endocrinology & Metabolic Specialty Pharmaceuticals
NAICS code1 code
  • Pharmaceutical Preparation Manufacturing325412
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Women's health biopharmaceuticals
Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Sojournix is a biotechnology company developing innovative medicines for women's health and endocrine disorders. The company is engaged in therapeutic research and clinical-stage drug development targeting these underserved disease areas, with operations supported by venture capital funding.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

VIVAIA is a sustainable footwear brand offering a comprehensive collection of comfortable shoes made from recycled plastic bottles. The product portfolio includes core footwear categories (Flats, Sneakers, Loafers, Boots, Heels, Sandals, and Kids shoes) as well as Bags & Accessories. The brand is organized around several named collections including Slip On Revolution, Sport Sandals, Lightweight Wonderland, and Walker Pro Collection, supported by two loyalty programs: V-PLUS (membership with discount benefits) and V-POINTS (rewards points system). The company emphasizes sustainability messaging, noting products are made from recycled materials including 6 plastic bottles per pair.

Recent move3 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight3 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

TherapeuticsMD was a women's-health-focused pharmaceutical company developing and commercializing products in menopause, hormone therapy, and reproductive health — directly comparable to Sojournix's stated women's health and endocrine focus. Both companies target the same prescriber base and similar patient populations in menopause and women's endocrine care.

TypeBroad incumbent
Description

Organon is a global women's health pharmaceutical company spun out of Merck, with a broad portfolio across contraception, fertility, menopause, and biosimilars. It is a broad incumbent serving the same end markets and patient populations Sojournix targets, but at a much larger scale and across many therapeutic areas.

TypeDirect peer
Description

Mithra is a Belgian specialty pharma focused on women's health, with development and commercialization programs in contraception, menopause (Estelle), and hormone therapy. It is a direct comparable in the women's-health specialty-pharma category Sojournix operates in.

TypeDirect peer
Description

Dare Bioscience is a clinical-stage biopharmaceutical company focused exclusively on women's health, with a portfolio spanning contraception, menopause, and reproductive health. It is a direct peer in business model, stage, and therapeutic focus to Sojournix.

5Estetra SRL (a Mithra subsidiary)
TypeEmerging player
Description

Estetra develops next-generation oral contraceptives and women's health products within the Mithra group, with focus on estrogen-based therapies. It is an emerging peer operating in overlapping women's endocrine indications relevant to Sojournix.

TypeBroad incumbent
Description

Astellas developed and commercializes Veozah (fezolinetant), an FDA-approved neurokinin 3 receptor antagonist for moderate-to-severe menopausal vasomotor symptoms — the most directly relevant large-pharma incumbent in Sojournix's likely target indication.

TypeBroad incumbent
Description

Bayer operates a global women's health franchise spanning contraception, menopause, and gynecological therapies. As a broad incumbent with deep commercial reach, it is a credible large-pharma comparator and a potential acquirer of specialty women's health assets.

8NeuroBo Therapeutics (DA-1726 / DA-1241)
TypeEmerging player
Description

NeuroBo Therapeutics is a clinical-stage biotech developing therapeutics that act on metabolic and endocrine pathways. It is an emerging peer in modality and stage to Sojournix, with overlap in endocrine-focused clinical development.

TypeBroad incumbent
Description

AbbVie has a meaningful endocrinology and women's health franchise (including elagolix via partnership) and is a large-pharma incumbent whose pipeline priorities overlap with Sojournix's therapeutic areas, particularly in reproductive and endocrine disorders.

TypeBroad incumbent
Description

Hologic is a women's-health-focused company spanning diagnostics, surgical, and increasingly therapeutics. While historically diagnostics-led, its strategic interest in women's health therapeutics makes it a comparable broad incumbent and a potential strategic acquirer.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks1 record

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance5 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors5 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Sojournix

Women's health biopharmaceuticalssojournixpharma.com

Sojournix is a private, clinical-stage biotechnology company founded in 2016 and headquartered in Arlington, Massachusetts, developing therapeutics for women's health and endocrine disorders, backed by approximately $70 million in venture funding from healthcare-focused investors.

What Sojournix does

Sojournix is a private, clinical-stage biotechnology company founded in 2016 and headquartered in Arlington, Massachusetts, focused on developing innovative therapeutics for women's health and endocrine disorders. The company operates with a small, specialized team of 11-50 employees, consistent with an R&D-driven organization at the preclinical-to-early-clinical stage.

Sojournix has financed its operations primarily through equity capital, completing three disclosed funding rounds that together total approximately $70 million. The most significant was a $44.0 million Series 3 closed in January 2019 and led by RA Capital Management, with participation from Boxer Capital, Frazier Healthcare Partners, Janus Henderson Investors, and Venrock Healthcare Capital Partners. Earlier rounds of $7.0 million (May 2017) and $19.0 million (December 2017) supported the company's earlier development work. The investor base is composed of dedicated healthcare-focused funds, which is consistent with a clinical pipeline rather than a commercial-stage operation.

The company is led by Daniel Grau as President, Chief Executive Officer, and Director, with Peter Lanciano serving as Chairman of the Board and Chairman of the Audit Committee. No commercial products, partnerships, licensing agreements, or revenue-generating activities were disclosed in the source material, and the company's therapeutic pipeline and specific drug candidates were not detailed. Note: scraped content from the sojournixpharma.com domain references unrelated third-party entities (a gambling platform and a footwear brand) and is not consistent with Sojournix's stated biotech focus, suggesting domain repurposing rather than first-party Sojournix content.

Sojournix firmographics

Firmographics
Name
Sojournix
Legal name
PEDANGWIN
Website
https://sojournixpharma.com
Company type
Private
Founded year
2016
Headcount range
11–50 employees
Short description
Sojournix is a private, clinical-stage biotechnology company founded in 2016 and headquartered in Arlington, Massachusetts, developing therapeutics for women's health and endocrine disorders, backed by approximately $70 million in venture funding from healthcare-focused investors.
Ownership category
akta.pro rank

Sojournix industry classification

Industry
Product category
Women's health biopharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAAAJ
Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAD
Endocrinology & Metabolic Specialty Pharmaceuticals

Keywords

  • Women's health therapeutics
  • Endocrine disorder treatments
  • Clinical-stage biopharmaceuticals
  • Women's health drug development
  • Endocrine medicine pipeline

Where Sojournix is headquartered

Location

Headquarters

HQ city
Waltham
HQ country
United States
HQ region
North America

Markets served

Sojournix business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Sojournix product offering

Product offering

Core offering

Sojournix is a biotechnology company developing innovative medicines for women's health and endocrine disorders. The company is engaged in therapeutic research and clinical-stage drug development targeting these underserved disease areas, with operations supported by venture capital funding.

Product overview

VIVAIA is a sustainable footwear brand offering a comprehensive collection of comfortable shoes made from recycled plastic bottles. The product portfolio includes core footwear categories (Flats, Sneakers, Loafers, Boots, Heels, Sandals, and Kids shoes) as well as Bags & Accessories. The brand is organized around several named collections including Slip On Revolution, Sport Sandals, Lightweight Wonderland, and Walker Pro Collection, supported by two loyalty programs: V-PLUS (membership with discount benefits) and V-POINTS (rewards points system). The company emphasizes sustainability messaging, noting products are made from recycled materials including 6 plastic bottles per pair.

Differentiator

Problem solved

Functional benefit

Companies that use Sojournix

Customer profile

Ideal customer profiles2 records

Sojournix technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Sojournix partnerships and signals

Strategic signal

Recent moves3 records

Expansion highlights3 records

Sojournix competitors and assessment

Company assessment

Direct peers

  • TherapeuticsMD: TherapeuticsMD was a women's-health-focused pharmaceutical company developing and commercializing products in menopause, hormone therapy, and reproductive health — directly comparable to Sojournix's stated women's health and endocrine focus. Both companies target the same prescriber base and similar patient populations in menopause and women's endocrine care.
  • Mithra Pharmaceuticals: Mithra is a Belgian specialty pharma focused on women's health, with development and commercialization programs in contraception, menopause (Estelle), and hormone therapy. It is a direct comparable in the women's-health specialty-pharma category Sojournix operates in.
  • Dare Bioscience: Dare Bioscience is a clinical-stage biopharmaceutical company focused exclusively on women's health, with a portfolio spanning contraception, menopause, and reproductive health. It is a direct peer in business model, stage, and therapeutic focus to Sojournix.

Broad incumbents

  • Organon & Co. Organon is a global women's health pharmaceutical company spun out of Merck, with a broad portfolio across contraception, fertility, menopause, and biosimilars. It is a broad incumbent serving the same end markets and patient populations Sojournix targets, but at a much larger scale and across many therapeutic areas.
  • Astellas Pharma (Veozah / fezolinetant): Astellas developed and commercializes Veozah (fezolinetant), an FDA-approved neurokinin 3 receptor antagonist for moderate-to-severe menopausal vasomotor symptoms — the most directly relevant large-pharma incumbent in Sojournix's likely target indication.
  • Bayer (Women's Health / menopause pipeline): Bayer operates a global women's health franchise spanning contraception, menopause, and gynecological therapies. As a broad incumbent with deep commercial reach, it is a credible large-pharma comparator and a potential acquirer of specialty women's health assets.
  • AbbVie (women's health and endocrinology): AbbVie has a meaningful endocrinology and women's health franchise (including elagolix via partnership) and is a large-pharma incumbent whose pipeline priorities overlap with Sojournix's therapeutic areas, particularly in reproductive and endocrine disorders.
  • Hologic (women's health diagnostics and therapeutics): Hologic is a women's-health-focused company spanning diagnostics, surgical, and increasingly therapeutics. While historically diagnostics-led, its strategic interest in women's health therapeutics makes it a comparable broad incumbent and a potential strategic acquirer.

Emerging players

  • Estetra SRL (a Mithra subsidiary): Estetra develops next-generation oral contraceptives and women's health products within the Mithra group, with focus on estrogen-based therapies. It is an emerging peer operating in overlapping women's endocrine indications relevant to Sojournix.
  • NeuroBo Therapeutics (DA-1726 / DA-1241): NeuroBo Therapeutics is a clinical-stage biotech developing therapeutics that act on metabolic and endocrine pathways. It is an emerging peer in modality and stage to Sojournix, with overlap in endocrine-focused clinical development.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks1 record

Key highlights5 records

Customer concentration

Sojournix social profiles

Digital presence

Sojournix compliance and trust

Trust signal

Compliance5 records

Sojournix financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Sojournix leadership team

Management profile

Number of profiles

Profiles2 records

Sojournix funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Sojournix M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Sojournix

What does Sojournix do?

Sojournix is a biotechnology company developing innovative medicines for women's health and endocrine disorders. The company is engaged in therapeutic research and clinical-stage drug development targeting these underserved disease areas, with operations supported by venture capital funding.

When was Sojournix founded?

Sojournix was founded in 2016. It employs 11 to 50 people.

Where is Sojournix based?

Sojournix is headquartered in Waltham, United States, in the North America region.

Who are Sojournix's main competitors?

Direct peers on record are TherapeuticsMD, Mithra Pharmaceuticals and Dare Bioscience. Broad incumbents are Organon & Co., Astellas Pharma (Veozah / fezolinetant), Bayer (Women's Health / menopause pipeline), AbbVie (women's health and endocrinology) and Hologic (women's health diagnostics and therapeutics). Emerging players are Estetra SRL (a Mithra subsidiary) and NeuroBo Therapeutics (DA-1726 / DA-1241).

Does Sojournix have an API?

No public API is recorded for Sojournix.

What industry is Sojournix in?

Sojournix's product category is Women's health biopharmaceuticals. Its primary akta.pro industry code is HLAIAAAJ, Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health), with a secondary code of HLAIACAD, Endocrinology & Metabolic Specialty Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireVasomotor Symptoms Market Size is Growing at a CAGR of 7% | Some of the Major Players are KaNDy Therapeutics, Fervent Pharmaceuticals, Astellas Pharma, Sojournix, Mitsubishi Tanabe PharmaDelveInsight released a market research report on vasomotor symptoms, forecasting growth through 2030. The report cites 41 million prevalent cases in 7MM countries in 2017, with the US accounting for 61% of the market. It highlights NK1/3 antagonists as a promising emerging therapy.PR NewswireSojournix CEO Speaks Today at LSX World Congress USASojournix, a clinical-stage biopharmaceutical company focused on women's health and neuroendocrine disorders, announced that CEO Daniel Grau will present at the LSX World Congress USA in Boston on October 7, 2019. The presentation will address business and financial challenges growth-stage companies face when securing later-stage investment as part of the Growth Stage CEO Forum.PR NewswireSojournix Poster Presentation At ENDO 2019 Features Positive Data From SJX-653 Proof-of-Mechanism Clinical StudySojournix presented positive data from a first-in-human Phase 1 clinical study of SJX-653 at ENDO 2019 in New Orleans, demonstrating clinical proof-of-mechanism for the NK3 antagonist as a non-hormonal treatment for menopausal vasomotor symptoms. The study showed statistically significant, dose-dependent reductions in luteinizing hormone (57% at 15mg) and testosterone (55% at 15mg) with a well-tolerated safety profile and pharmacokinetics supporting once-daily dosing. The company indicated this represents an important development milestone toward addressing a significant unmet medical need for safe, effective non-hormonal VMS treatments.PR NewswireSojournix To Present At Cowen And Company 39th Annual Health Care ConferenceSojournix, a clinical-stage biopharmaceutical company focused on women's health and neuroendocrine disorders, announced that CEO Daniel Grau will present at the Cowen and Company 39th Annual Health Care Conference on March 13, 2019 in Boston. The company is developing SJX-653, a novel NK3 antagonist as a non-hormonal treatment for vasomotor symptoms associated with menopause. This presentation is part of routine investor relations activity at a major healthcare conference.PR NewswireSojournix Announces Positive Top-Line Phase 1 Data Demonstrating Clinical Proof of Mechanism and Once-Daily (QD) Pharmacokinetics for SJX-653Sojournix announced positive top-line data from a first-in-human Phase 1 clinical study of SJX-653, a novel neurokinin-3 (NK3) receptor antagonist being developed as a once-daily non-hormonal therapy for menopausal vasomotor symptoms. The study demonstrated clinical proof-of-mechanism with statistically significant dose-dependent reductions in luteinizing hormone (70%, p=0.0006) and testosterone (68%, p<0.0001), along with favorable tolerability and a half-life supporting once-daily dosing. The company is currently evaluating SJX-653 in ongoing Phase 1 studies in postmenopausal women and plans to advance into a Phase 2 clinical trial.PR NewswireSojournix Appoints Ruth Thieroff-Ekerdt, M.D. As Senior Vice President And Chief Medical OfficerSojournix appointed Ruth Thieroff-Ekerdt, M.D., as Senior Vice President and Chief Medical Officer to lead the clinical development of its drug candidate SJX-653. Dr. Thieroff-Ekerdt brings over three decades of experience in clinical development and regulatory submissions across various therapeutic areas to the role. The company aims to advance SJX-653 as a non-hormonal treatment for moderate to severe vasomotor symptoms associated with menopause.FinSMEsSojournix Completes $44M Series C FinancingSojournix completed a $44M Series C financing, bringing total capital raised to $70M. The funds will advance SJX-653, a NK3 receptor antagonist in Phase 1 clinical studies for menopausal hot flashes. The company plans to use the capital to further develop the drug.PR NewswireSojournix Completes $44 Million Series C FinancingSojournix announced the completion of a $44 million Series C financing on January 3, 2019, aimed at advancing its clinical development of SJX-653, a neurokinin-3 receptor antagonist for treating menopausal vasomotor symptoms. The financing attracted participation from prominent healthcare investors, underscoring the company's commitment to addressing a significant medical need in women's health. Sojournix has now raised a total of $70 million in capital since its inception.